Entries by

Haoma Medica completes first-in-human trial for NaQuinate

The first-in-human trial initiated last year in healthy adults studied single and multiple doses of NaQuinate. The primary objective was to assess the safety, tolerability and pharmacokinetics. ”We The post Haoma Medica completes first-in-human trial for NaQuinate appeared first on Pharmaceutical Business review.

FDA defers approval of DaxibotulinumtoxinA for Injection in glabellar lines due to Covid-19 related travel restrictions

In a communication received on November 24, 2020, the FDA reiterated that an inspection of the company’s manufacturing facility is required as part of the BLA approval process. The post FDA defers approval of DaxibotulinumtoxinA for Injection in glabellar lines due to Covid-19 related travel restrictions appeared first on Pharmaceutical Business review.